Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ordaya, Eloy E, Beam, Elena, Yao, Joseph D, Razonable, Raymund R, Vergidis, Paschalis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214166/
https://www.ncbi.nlm.nih.gov/pubmed/35859990
http://dx.doi.org/10.1093/ofid/ofac283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214166/
https://www.ncbi.nlm.nih.gov/pubmed/35859990
http://dx.doi.org/10.1093/ofid/ofac283

Ejemplares similares